Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences. In both studies, adults with active CDI were randomized to receive blinded fidaxomicin 200 mg twice daily...
Main Authors: | Crook, D, Walker, A, Kean, Y, Weiss, K, Cornely, O, Miller, M, Esposito, R, Louie, T, Stoesser, N, Young, B, Angus, B, Gorbach, S, Peto, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
by: Cornely, O, et al.
Published: (2012) -
Factors Influencing Time to Resolution of Diarrhea in Patients with Clostridium difficile Infection Treated with Fidaxomicin or Vancomycin.
by: Gerding, D, et al.
Published: (2012) -
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
by: Cornely, O, et al.
Published: (2012) -
Clostridium difficile in 7 European countries and North America: Fidaxomicin vs vancomycin therapy
by: Crook, D, et al.
Published: (2012) -
Effect of Proton Pump Inhibitors (PPI) and H2 Receptor Antagonists (H2RA) on Response to Therapy with Fidaxomicin or Vancomycin in Hospitalized Patients with Clostridium difficile Infection
by: Weiss, K, et al.
Published: (2011)